Related Experiment Video

Updated: Mar 7, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

7.0K

HSP90 as a novel molecular target in non-small-cell lung cancer

Khashayar Esfahani1, Victor Cohen1

  • 1Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada.

Lung Cancer (Auckland, N.Z.)
|February 18, 2017
PubMed

Insights

Lung cancer is a leading cause of death. While targeted therapies show promise for non-small-cell lung cancer (NSCLC), drug resistance limits long-term patient benefit.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer is a significant global health burden, causing numerous deaths annually.
  • Advances in understanding driver mutations have revolutionized non-small-cell lung cancer (NSCLC) treatment.
  • Targeted therapies for EGFR and ALK mutations are standard first-line treatments for NSCLC.

Purpose of the Study:

  • To investigate the mechanisms of acquired resistance to targeted therapies in NSCLC.
  • To identify potential strategies to overcome or delay the development of resistance.
  • To improve long-term outcomes for patients with EGFR- or ALK-mutated NSCLC.

Main Methods:

  • Analysis of patient tumor samples before and after treatment.
  • Genomic profiling to identify resistance mutations.
  • In vitro and in vivo models to study resistance mechanisms.
  • Evaluation of combination therapies or novel agents.

Main Results:

  • Acquired resistance is a common clinical challenge, emerging within 8-12 months.
  • Specific genetic alterations are identified as key drivers of resistance.
  • Preclinical models confirm the role of these alterations in treatment failure.
  • Initial responses to targeted therapies are often robust but transient.

Conclusions:

  • Drug resistance remains a critical barrier to durable responses in NSCLC.
  • Understanding resistance mechanisms is crucial for developing next-generation therapies.
  • Further research is needed to overcome acquired resistance and improve patient survival in NSCLC.
Keywords:
driver mutationsheat shock protein 90 (HSP90)non-small-cell lung cancertargeted therapy

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K